VPC

Vestal Point Capital Portfolio holdings

AUM $2.73B
1-Year Est. Return 128.57%
This Fund
S&P 500
This Quarter Est. Return
1 Year Est. Return
+128.57%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$2.2B
AUM Growth
+$305M
Cap. Flow
Cap. Flow %
Top 10 Hldgs %
Holding
95
New
Increased
Reduced
Closed

Top Buys

1
+$74.6M
2
+$61.3M
3
+$55.7M
4
DXCM icon
DexCom
DXCM
+$51.4M
5
RGEN icon
Repligen
RGEN
+$48.6M

Top Sells

1
+$108M
2
+$92.7M
3
+$84M
4
QURE icon
uniQure
QURE
+$63.1M
5
KALV icon
KalVista Pharmaceuticals
KALV
+$54.2M

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OKUR
76
OnKure Therapeutics
OKUR
$48M
$1.75M 0.08%
635,000
LUNG icon
77
Pulmonx
LUNG
$73.6M
$1.34M 0.06%
+830,000
MGNX icon
78
MacroGenics
MGNX
$217M
$470K 0.02%
280,000
TENX icon
79
Tenax Therapeutics
TENX
$90.6M
$407K 0.02%
53,439
TRAW icon
80
Traws Pharma
TRAW
$13.8M
$278K 0.01%
150,000
+200
ATRA icon
81
Atara Biotherapeutics
ATRA
$45.4M
– –
-94,085
BHVN icon
82
Biohaven
BHVN
$1.54B
– –
0
COGT icon
83
Cogent Biosciences
COGT
$5.95B
– –
-3,080,000
COO icon
84
Cooper Companies
COO
$14.5B
– –
-350,000
EW icon
85
Edwards Lifesciences
EW
$49.8B
– –
-300,000
GEHC icon
86
GE HealthCare
GEHC
$33.1B
– –
-700,000
GPCR icon
87
Structure Therapeutics
GPCR
$4.12B
– –
-1,200,000
MDT icon
88
Medtronic
MDT
$115B
– –
-195,000
MLTX icon
89
MoonLake Immunotherapeutics
MLTX
$1.32B
– –
-550,000
NBIX icon
90
Neurocrine Biosciences
NBIX
$13B
– –
-30,000
PRGO icon
91
Perrigo
PRGO
$1.39B
– –
-625,000
TMO icon
92
Thermo Fisher Scientific
TMO
$186B
– –
-25,000
TVTX icon
93
Travere Therapeutics
TVTX
$2.64B
– –
-355,000
VRDN icon
94
Viridian Therapeutics
VRDN
$2.98B
– –
-100,000
ZBH icon
95
Zimmer Biomet
ZBH
$17.9B
– –
-50,000
1 2 3
4